Assessment of Qualitative breast Cancer Characteristic (Article Review)

Henry NL, Shah PD, Haider I, Freer PE, Jagsi R, Sabel MS. Chapter 88: Cancer of the Breast. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa: Elsevier; 2020. Jagsi R, King TA, Lehman C, Morrow M, Harris JR, Burstein HJ. Chapter 79: Malignant Tumors of the Breast. In: DeVita VT, Lawrence TS, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 11th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2019. National Cancer Institute. Physician Data Query (PDQ). Breast Cancer Treatment – Patient Version. 2021. Accessed at https://www.cancer.gov/types/breast/patient/breast-treatment- pdq on June 24, 2021. Brinton L.A., Schairer C., Hoover R.N., Fraumeni J.F., Jr. Menstrual Factors and Risk of Breast Cancer. Cancer Investig. 1988;6:245–254. doi: 10.3109/07357908809080645. Collaborative Group on Hormonal Factors in Breast Cancer Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118?964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13:1141–1151. doi: 10.1016/S1470-2045(12)70425-4. De Blok C.J.M., Wiepjes C.M., Nota N.M., van Engelen K., Adank M.A., Dreijerink K.M.A., Barbé E., Konings I.R.H.M., den Heijer M. Breast cancer risk in transgender people receiving hormone treatment: Nationwide cohort study in the Netherlands. BMJ. 2019;365:l1652. doi: 10.1136/bmj.l1652. Vinogradova Y., Coupland C., Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: Nested case-control studies using the QResearch and CPRD databases. BMJ. 2020;371:m3873. doi: 10.1136/bmj.m3873. Yue W., Wang J.P., Li Y., Fan P., Liu G., Zhang N., Conaway M., Wang H., Korach K.S., Bocchinfuso W., et al. Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms. Int. J. Cancer. 2010;127:1748–1757. doi: 10.1002/ijc.25207. [DOI] [PMC free article] [PubMed] [Google Scholar] Dall G.V., Britt K.L. Estrogen Effects on the Mammary Gland in Early and Late Life and Breast Cancer Risk. Front. Oncol. 2017;7:110. doi: 10.3389/fonc.2017.00110. [DOI] [PMC free article] [PubMed] [Google Scholar] Singletary S.E. Rating the risk factors for breast cancer. Ann. Surg. 2003;237:474–482. doi: 10.1097/01.SLA.0000059969.64262.87. [DOI] [PMC free article] [PubMed] [Google Scholar] Harlow S.D., Paramsothy P. Menstruation and the menopausal transition. Obstet. Gynecol. Clin. N. Am. 2011;38:595–607. doi: 10.1016/j.ogc.2011.05.010. [DOI] [PMC free article] [PubMed] [Google Scholar] Kelsey J.L., Gammon M.D., John E.M. Reproductive factors and breast cancer. Epidemiol. Rev. 1993;15:36–47. doi: 10.1093/oxfordjournals.epirev.a036115. [DOI] [PubMed] [Google Scholar] Hershman, D. L. et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 32, 1941–1967 (2014). Hanai, A. et al. Effects of cryotherapy on objective and subjective symptoms of paclitaxel- induced neuropathy: prospective self-controlled trial. J. Natl Cancer Inst. 110, 141–148 (2018). Kadakia, K. C., Rozell, S. A., Butala, A. A. & Loprinzi, C. L. Supportive cryotherapy: a review from head to toe. J. Pain Symptom Manage. 47, 1100–1115 (2014). Hou, S., Huh, B., Kim, H. K., Kim, K.-H. & Abdi, S. Treatment of chemotherapy-induced peripheral neuropathy: systematic review and recommendations. Pain Physician 21, 571– 592 (2018). Ahmed, R. L., Schmitz, K. H., Prizment, A. E. & Folsom, A. R. Risk factors for lymphedema in breast cancer survivors, the Iowa Women’s Health Study. Breast Cancer Res. Treat. 130, 981–991 (2011). Gillespie, T. C., Sayegh, H. E., Brunelle, C. L., Daniell, K. M. & Taghian, A. G. Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland. Surg. 7, 379–403 (2018). Runowicz, C. D. et al. American Cancer Society/ American Society of Clinical Oncology breast cancer survivorship care guideline. J. Clin. Oncol. 34, 611–635 (2016). Velikova, G. et al. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncol. 19, 1516–1529 (2018). Hofmann, D. et al. WSG ADAPT — adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials 14, 261 (2013). Robertson, J. F. R., Dowsett, M. & Bliss, J. M. Peri-operative aromatase inhibitor treatment in determining or predicting long-term outcome in early breast cancer — the POETIC Trial (CRUK/07/015) [abstract]. SABCS GS1-03 (2017). . Kim, S.-B. et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebocontrolled, phase 2 trial. Lancet Oncol. 18, 1360–1372 (2017). Schmid, P. et al. AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): a randomised, double-blind, placebo-controlled, phase II trial. J. Clin. Oncol. 36 (15 Suppl.), 1007 (2018). Jones, R. H. et al. Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): a randomized, double-blind, placebo-controlled, phase II trial [abstract]. J. Clin. Oncol. 37 (no. 15_suppl), 1005–1005 (2019). Yardley, D. A. et al. Randomized phase II, doubleblind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptorpositive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J. Clin. Oncol. 31, 2128–2135 (2013). Ogitani, Y. et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA Topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin. Cancer Res. 22, 5097–5108 (2016). Tamura, K. et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2- positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 20, 816–826 (2019). Burris III, H. A., Giaccone, G. & Im, S. A. Updated findings of a first-in-human phase 1 study of margetuximab, an Fc-optimized chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors [abstract]. Am. Soc. Clin. Oncol. Meet. 33 (no. 15_suppl), A523 (2015). Rugo, H. S. et al. SOPHIA primary analysis: a phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx) [abstract]. J. Clin. Oncol. 37 (Suppl.), Abstr 1000 (2019). Hyman, D. M., Piha-Paul, S. & Rodon, J. Neratinib in HER2- or HER3-mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 ‘basket’ study [abstract]. Am. Assoc. Cancer Res. Meet. CT001 (2017). Kanemura, S., I. Tsuji, N. Ohuchi, H. Takei, T. Yokoe, Y. Koibuchi, K. Ohnuki, A. Fukao, S. Satomi, and S. Hisamichi. 1999. "A case control study on the effectiveness of breast cancer screening by clinical breast examination in Japan." Jpn J Cancer Res no. 90 (6):607- doi: S0910505099801240 [pii]. Kardinah, D., B. O. Anderson, C. Duggan, I. A. Ali, and D. B. Thomas. 2013. "Short report: Limited effectiveness of screening mammography in addition to clinical breast examination by trained nurse midwiv